AbbVie announced a $1.4 billion manufacturing investment in Durham, North Carolina, building an approximately 185-acre campus near Research Triangle Park. The project aims to expand production capacity for sterile, injectable pharmaceutical products used across AbbVie’s immunology, neuroscience, and oncology portfolio. The company plans to begin construction this year, with completion expected by the end of 2028, and targets hiring 734 people across engineers, scientists, production staff, and lab roles. AbbVie said it will implement AI to support production operations. A job development investment grant approved by North Carolina’s government would reimburse AbbVie up to $19.3 million over 12 years, tied to verified incremental hiring and investment milestones. For biotech and med-tech manufacturers, the campus investment highlights sustained U.S. capacity buildout for injectable drug forms and the increasing use of AI inside sterile manufacturing workflows.